OnQuality announces FDA clearance of IND for OQL011
- May 24, 2019
- 1 min read
Updated: May 20, 2021
Shanghai, China—May 24th, 2019. OnQuality Pharmaceuticals Ltd., today announced the U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug Application for OQL011, to proceed into a Phase II clinical trial to evaluate its safety and efficacy in the treatment of hand-foot skin reaction induced by VEGFR inhibitors in cancer patients
About Hand-Foot Skin Reaction (HFSR)
HFSR is a common cutaneous toxicity induced by the multi-tyrosine kinase inhibitors, which are known as targeted oncology therapeutics.
About OnQuality Pharmaceuticals
OnQuality Pharmaceuticals is dedicated to pioneering the discovery and development of mechanism-based therapies that have the potential to improve both quality-of-life and outcomes for cancer patients by managing the dose-limiting toxicities of cancer therapeutics.
Commentaires